Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Dazostinag sodium by Takeda Pharmaceutical for Paranasal Sinus And Nasal Cavity Cancer: Likelihood of Approval
Dazostinag sodium is under clinical development by Takeda Pharmaceutical and currently in Phase II for Paranasal Sinus And Nasal Cavity...
Dazostinag sodium by Takeda Pharmaceutical for Hypopharyngeal Cancer: Likelihood of Approval
Dazostinag sodium is under clinical development by Takeda Pharmaceutical and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData,...
Dazostinag sodium by Takeda Pharmaceutical for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Dazostinag sodium is under clinical development by Takeda Pharmaceutical and currently in Phase II for Oral Cavity (Mouth) Cancer. According...
Dazostinag sodium by Takeda Pharmaceutical for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Dazostinag sodium is under clinical development by Takeda Pharmaceutical and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According...
Dazostinag sodium by Takeda Pharmaceutical for Oropharyngeal Cancer: Likelihood of Approval
Dazostinag sodium is under clinical development by Takeda Pharmaceutical and currently in Phase II for Oropharyngeal Cancer. According to GlobalData,...
Dazostinag sodium by Takeda Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of Approval
Dazostinag sodium is under clinical development by Takeda Pharmaceutical and currently in Phase I for Non-Small Cell Lung Cancer. According...